var data={"title":"Methylphenidate: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Methylphenidate: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6566?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=methylphenidate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Methylphenidate: Patient drug information&quot;</a> and <a href=\"topic.htm?path=methylphenidate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Methylphenidate: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709144\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Abuse and dependence:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">CNS stimulants, including methylphenidate-containing products and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">Long-term abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use because severe depression may occur. Withdrawal following long-term therapeutic use may unmask symptoms of the underlying disorder that may require follow-up.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195295\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aptensio XR;</li>\n      <li>Concerta;</li>\n      <li>Cotempla XR-ODT;</li>\n      <li>Daytrana;</li>\n      <li>Metadate CD [DSC];</li>\n      <li>Metadate ER;</li>\n      <li>Methylin;</li>\n      <li>QuilliChew ER;</li>\n      <li>Quillivant XR;</li>\n      <li>Ritalin;</li>\n      <li>Ritalin LA;</li>\n      <li>Ritalin SR [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195296\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Biphentin;</li>\n      <li>Concerta;</li>\n      <li>Foquest;</li>\n      <li>Ritalin;</li>\n      <li>Ritalin SR</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195328\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Central Nervous System Stimulant</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195300\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ADHD: </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Immediate release (IR) products (tablets, chewable tablets, and solution): </i></b> Initial: 5 mg twice daily, before breakfast and lunch; increase by 5 to 10 mg daily at weekly intervals; maximum dose: 60 mg/day (in 2 to 3 divided doses).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Extended release (ER), sustained release (SR) products (capsules, tablets, chewable tablets, <i><b>orally disintegrating tablets</b></i>, and oral suspension): </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Concerta:</i> (Adults &lt;65 years):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients not currently taking methylphenidate: Initial: 18 to 36 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients currently taking immediate release (IR) methylphenidate or sustained release (SR) [Canadian product]: Initial: <b>Note:</b> Dosing based on current regimen and clinical judgment; suggested dosing listed below:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>IR methylphenidate:</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">- Patients taking IR methylphenidate 5 mg 2 to 3 times daily: 18 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">- Patients taking IR methylphenidate 10 mg 2 to 3 times daily: 36 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">- Patients taking IR methylphenidate 15 mg 2 to 3 times daily: 54 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">- Patients taking IR methylphenidate 20 mg 2 to 3 times daily: 72 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>SR methylphenidate (Concerta Canadian product labeling 2017):</i></p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">- Patients taking methylphenidate SR 20 mg daily: 18 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">- Patients taking methylphenidate SR 40 mg daily: 36 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">- Patients taking methylphenidate SR 60 mg daily: 54 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Dose adjustment: May increase dose in increments of 18 mg at weekly intervals. A dosage strength of 27 mg is available for situations in which a dosage between 18 to 36 mg is desired. Maximum dose: 72 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Aptensio XR:</i> Initial: 10 mg once daily; may be titrated in 10 mg increments at weekly intervals; maximum: 60 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Biphentin [Canadian product]:</i> Patients not currently taking methylphenidate: Initial: 10 to 20 mg once daily; may be adjusted in 10 mg increments at weekly intervals to a maximum dose of 80 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from immediate release methylphenidate formulations to Biphentin:</i> Use equivalent total daily dose administered once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Foquest [Canadian product]: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients not currently taking methylphenidate: Initial: 25 mg once daily; adjust dose at 5 day intervals as needed to the lowest effective dose (maximum: 100 mg/day).</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Patients currently taking methylphenidate: Initiate Foquest with the next lower strength based on total methylphenidate daily dose; adjust dose at 5 day intervals as needed to the lowest effective dose (maximum: 100 mg/day). <b>Note:</b> Do not substitute immediate release formulations or other controlled release formulations with Foquest on a milligram for milligram basis (pharmacokinetic profiles differ).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Metadate ER, Ritalin-SR:</i> May be given in place of immediate release products (duration of action ~8 hours), once the immediate release formulation daily dose is titrated and the titrated 8-hour dosage corresponds to sustained or extended release tablet size; maximum: 60 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Metadate CD, Quillivant XR:</i> Initial: 20 mg once daily; may be adjusted in 10 to 20 mg increments at weekly intervals; maximum: 60 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from other methylphenidate formulations to Quillivant XR: </i>Discontinue previous formulation and titrate using above schedule; do not substitute on a milligram-per-milligram basis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>QuilliChew E</i>\n      <i>R:</i> Initial: 20 mg once daily in the morning; may be adjusted by 10, 15 or 20 mg at weekly intervals (tablets are scored and may be broken in half to achieve the 10 mg and 15 mg doses); maximum: 60 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from other methylphenidate formulations to QuilliChew ER: </i> Discontinue previous formulation and titrate using above schedule; do not substitute on a milligram-per-milligram basis</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Ritalin LA</i>: Initial: 20 mg once daily (10 mg once daily may be considered for some patients); may be adjusted in 10 mg increments at weekly intervals; maximum: 60 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Conversion from immediate release or sustained release methylphenidate formulation to Ritalin LA:</i> Use equivalent total daily dose administered once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Narcolepsy:</b> Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Immediate release tablets and solution </i></b>\n      <i> (Methylin, Ritalin):</i> Initial: 5 mg twice daily before breakfast and lunch; increase by 5 to 10 mg daily at weekly intervals; maximum dose: 60 mg/day (in 2 to 3 divided doses).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Extended and sustained release tablets </i></b> <i>(Metadate ER, Ritalin-SR):</i> May be given in place of immediate release products (duration of action ~8 hours), once the immediate release formulation daily dose is titrated and the titrated 8-hour dosage corresponds to sustained or extended release tablet size; maximum: 60 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Depression in medically-ill older adults or adult patients with terminal illness and/or receiving palliative care (off-label use):</b> Oral: Initial: <b><i>Immediate release: </i></b>2.5 to 5 mg once daily before breakfast or twice daily before breakfast and lunch; increase by 2.5 to 5 mg daily every 1 to 3 days in divided doses before breakfast and lunch as tolerated; maximum dose: 20 to 40 mg/day (Hardy, 2009; Kerr 2012). <i>Do<b> not </b>use sustained release product.</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Fatigue, cancer-related (off-label use):</b> Oral: Immediate release: Initial: 5 mg twice daily (at 8 am and 1 pm); increase based on tolerability in increments of 10 mg/day every 3 days up to a maximum of 40 mg/day (Kerr 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195313\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=methylphenidate-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Methylphenidate: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ADHD:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Oral, immediate release (IR) products (tablets, chewable tablets, and solution): </i></b> Children &ge;6 years and Adolescents: Initial: 5 mg twice daily, before breakfast and lunch; increase by 5 to 10 mg daily at weekly intervals; maximum dose: 60 mg/day (in 2 to 3 divided doses).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Oral, extended release (ER), sustained release (SR) products (capsules, tablets, chewable tablets, <i><b>orally disintegrating tablets, </b></i>and oral suspension): </i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;6 years and Adolescents &lt;18 years:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Concerta:</i> <b>Note:</b> For adolescents &ge;18 years, refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patients not currently taking methylphenidate: Initial: 18 mg once daily in the morning</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Patients currently taking immediate release (IR) methylphenidate or sustained release (SR) [Canadian product]: Initial: <b>Note:</b> Dosing based on current regimen and clinical judgment; suggested dosing listed below:</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>IR methylphenidate:</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">- Patients taking IR methylphenidate 5 mg 2 to 3 times daily: 18 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">- Patients taking IR methylphenidate 10 mg 2 to 3 times daily: 36 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">- Patients taking IR methylphenidate 15 mg 2 to 3 times daily: 54 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">- Patients taking IR methylphenidate 20 mg 2 to 3 times daily: 72 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <i>SR methylphenidate (Concerta Canadian product labeling 2017):</i></p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">- Patients taking methylphenidate SR 20 mg daily: 18 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">- Patients taking methylphenidate SR 40 mg daily: 36 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">- Patients taking methylphenidate SR 60 mg daily: 54 mg once every morning</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Dose adjustment: May increase dose in increments of 18 mg at weekly intervals. A dosage strength of 27 mg is available for situations in which a dosage between 18 to 36 mg is desired.</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">\n      <b>Maximum dose:</b> 54 mg/day in children 6 to 12 years <b>or</b> 2 mg/kg/day (up to 72 mg/day) in adolescents &lt;18 years</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Cotempla XR-ODT: </i>Initial: 17.3 once daily; increase weekly in 8.6 to 17.3 mg increments; maximum dose: 51.8 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;6 years and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Aptensio XR:</i> Initial: 10 mg once daily; may be titrated in 10 mg increments at weekly intervals; maximum: 60 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Biphentin [Canadian product]:</i> Patients not currently taking methylphenidate: Initial: 10 to 20 mg once daily; may be adjusted in 10 mg increments at weekly intervals. Maximum: 60 mg/day. <b>Note:</b> In some children &gt;60 kg, a maximum dose of 1 mg/kg/day (not to exceed 80 mg/day) may be necessary; however, close monitoring for adverse events is required. Reduce dose or discontinue if adverse events arise.</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Conversion from immediate-release methylphenidate formulations to Biphentin:</i> Use equivalent total daily dose administered once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Metadate ER, Ritalin-SR:</i> May be given in place of immediate release products (duration of action ~8 hours), once the immediate release formulation daily dose is titrated and the titrated 8-hour dosage corresponds to sustained or extended release tablet size; maximum: 60 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Metadate CD, Quillivant XR:</i> Initial: 20 mg once daily; may be adjusted in 10 to 20 mg increments at weekly intervals; maximum: 60 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i> Conversion from other methylphenidate formulations to Quillivant XR: </i>Discontinue previous formulation and titrate using above schedule; do not substitute on a milligram-per-milligram basis</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>QuilliChew ER:</i> Initial: 20 mg once daily in the morning; may be adjusted by 10, 15 or 20 mg at weekly intervals (tablets are scored and may be broken in half to achieve the 10 mg and 15 mg doses); maximum: 60 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Conversion from other methylphenidate formulations to QuilliChew ER:</i> Discontinue previous formulation and titrate using above schedule; do not substitute on a milligram-per-milligram basis</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Ritalin LA</i>: Initial: 20 mg once daily (10 mg once daily may be considered for some patients); may be adjusted in 10 mg increments at weekly intervals; maximum: 60 mg/day</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">\n      <i>Conversion from immediate-release or sustained-release methylphenidate formulation to Ritalin LA:</i> Use equivalent total daily dose administered once daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Transdermal:</i></b> (Daytrana): Children &ge;6 years and Adolescents &lt;18 years: Initial: 10 mg patch once daily; remove up to 9 hours after application. Titrate based on response and tolerability; may increase to next transdermal dose no more frequently than every week. <b>Note:</b> Application should occur 2 hours prior to desired effect. Drug absorption may continue for a period of time after patch removal. The prescribing information recommends patients converting from another formulation of methylphenidate should be initiated at 10 mg regardless of their previous dose and titrated as needed due to the differences in bioavailability of the transdermal formulation. However, some clinicians have supported higher starting patch doses for patients converting from oral methylphenidate doses of &gt;20 mg daily; for example, the 15 mg (18.75 cm<sup>2</sup>) patch has been investigated to have the same effect as 22.5 mg daily of the immediate release preparation, 27 mg/day of the osmotic release preparation, or 20 mg daily of the encapsulated bead preparation (Arnold, 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Narcolepsy:</b> Oral: Children &ge;6 years and Adolescents: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195301\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>ADHD/Narcolepsy:</b> Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Major depressive disorder (antidepressant augmentation; off-label use):</b> Oral: Initial: <b><i>Immediate release:</i></b> 2.5 mg twice daily (given at 9 am and 3 pm); increase dosage based on response and tolerability in increments of 2.5 mg twice daily every 3 to 4 days up to 40 mg/day.  Average dose in clinical trials was ~15 to 16 mg/day (Lavrestky 2015; Lavrestky 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15967082\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); undergoes extensive metabolism to a renally eliminated metabolite with little or no pharmacologic activity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F15967083\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Transdermal: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195272\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate CD: 10 mg [DSC], 20 mg [DSC], 30 mg [DSC] [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate CD: 40 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate CD: 50 mg [DSC] [contains fd&amp;c blue #2 (indigotine)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate CD: 60 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Capsule Extended Release 24 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptensio XR: 10 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptensio XR: 15 mg [contains fd&amp;c red #40, fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptensio XR: 20 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptensio XR: 30 mg [contains brilliant blue fcf (fd&amp;c blue #1)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptensio XR: 40 mg [contains brilliant blue fcf (fd&amp;c blue #1), fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptensio XR: 50 mg [contains fd&amp;c yellow #10 (quinoline yellow)]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Aptensio XR: 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ritalin LA: 10 mg, 20 mg, 30 mg, 40 mg, 60 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 20 mg, 30 mg, 40 mg, 60 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Patch, Transdermal: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Daytrana: 10 mg/9 hr (30 ea); 15 mg/9 hr (30 ea); 20 mg/9 hr (30 ea); 30 mg/9 hr (30 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Methylin: 5 mg/5 mL (500 mL); 10 mg/5 mL (500 mL) [contains polyethylene glycol; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/5 mL (500 mL); 10 mg/5 mL (500 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension Reconstituted, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Quillivant XR: 25 mg/5 mL (60 mL, 120 mL, 150 mL, 180 mL) [contains sodium benzoate; banana flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ritalin: 5 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ritalin: 10 mg, 20 mg [scored]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg, 10 mg, 20 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Methylin: 2.5 mg [DSC], 5 mg [DSC] [contains aspartame; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Methylin: 10 mg [DSC] [scored; contains aspartame; grape flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 2.5 mg, 5 mg, 10 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable Extended Release, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">QuilliChew ER: 20 mg, 30 mg, 40 mg [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Concerta: 18 mg, 27 mg, 36 mg, 54 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate ER: 20 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate ER: 20 mg [additive free, color free]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ritalin SR: 20 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 10 mg, 18 mg, 20 mg, 27 mg, 36 mg, 54 mg, 72 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release 24 Hour, Oral, as hydrochloride: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 18 mg, 27 mg, 36 mg, 54 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Extended Release Disintegrating, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cotempla XR-ODT: 8.6 mg, 17.3 mg, 25.9 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195256\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50474161\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aptensio XR capsules contain multi layered beads. The immediate release layer delivers approximately 40% of the methylphenidate dose, and the controlled release layer delivers approximately 60% of the methylphenidate dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Concerta is an osmotic controlled release formulation (OROS) of methylphenidate. The tablet has an immediate-release overcoat providing an initial dose of methylphenidate within 1 hour, and the remaining is released at a controlled rate over 5-9 hours. The overcoat covers a trilayer core. The trilayer core is composed of two layers containing the drug and excipients, and one layer of osmotic components. As water from the gastrointestinal tract enters the core, the osmotic components expand and methylphenidate is released.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metadate CD capsules contain a mixture of immediate release and extended release beads, designed to release 30% of the dose immediately and 70% over an extended period.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ritalin LA uses Spheroidal Oral Drug Absorption System (SODAS) design to deliver a bimodal release of medication, intended to mimic twice-daily administration of immediate-release methylphenidate. Fifty percent of the drug is delivered in immediate-release beads, and the remaining half is delivered in delayed-release beads approximately 4 hours after administration.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F17983297\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Capsule, Controlled Release, Oral, as hydrochloride:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Biphentin: 10 mg, 15 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 80 mg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Foquest: 25 mg, 35 mg, 45 mg, 55 mg, 70 mg, 85 mg, 100 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195330\" class=\"block csi drugH1Div\"><span class=\"drugH1\">Controlled Substance</span>\n    <p style=\"text-indent:0em;display:inline\">C-II</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7874704\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Concerta: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021121s038lbl.pdf&amp;token=Z3+5wLFH3tbNKqerxb4rrYGgnvPKRaIZnQH7WzBjgt4YhDV2GaSAQFq1gmZYkbziN11EmR5LzJ//gVAClSc+/PfF7W1uhP9MMaem3oVOadU=&amp;TOPIC_ID=9638\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021121s038lbl.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cotempla XR-ODT: <a target=\"_blank\" href=\"https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205489s000lbl.pdf#page=21&amp;token=hfBmR9RBX+ETlSnjOLqpNufD+9B1oBEyX47XfFIbEjoUPmLdATz/IBQYGzIxkv0qcMfOOCS0C4SJ4Bavpt6PleDDOCsL09JCZ0oZmHGxiOfzAev3ihmt6fuYphScy1TH&amp;TOPIC_ID=9638\" target=\"_blank\">https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205489s000lbl.pdf#page=21</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Daytrana: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021514s025lbl.pdf#page=25&amp;token=MG6Knd8P0QaiY2u1/YPtvSAnaSm8kaA06PpiNE83OZ74NQFxjYstit4gdCjFPT3E1ZDsUyoVqHRINNlUA93bvhZLexc9T2MUcxEOL1oMEhYBIeMfXenGCV7ahyFf4xU8&amp;TOPIC_ID=9638\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021514s025lbl.pdf#page=25</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Metadate CD: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021259s030lbl.pdf#page=20&amp;token=eSWHIQ4h88SNHJaQVikS9+AiCTVS4TC06dG1sqybMLxDu6czA7/FbeyP08X1CpRoNpP/logApLwh2jIxSgPOJDT2m5QSNAdvrIcId4/DHxUqFR8npJnHXN7DeDfPEanx&amp;TOPIC_ID=9638\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021259s030lbl.pdf#page=20</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Methylin chewable tablet: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021475s010lbl.pdf#page=13&amp;token=Glgv7mddSmgjPHmmhX1L6XudUZP6Bycwt/9HtKXnTrYXNW5PcHnBMNwCy+3TE1kE/fRc9t6B6Ww8jJUrB8Jdw7YddV4xVcJ7H5qTcFzgvyAhmQmV/uYtDbkJ2e8jxNsM&amp;TOPIC_ID=9638\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021475s010lbl.pdf#page=13</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Methylin immediate release oral solution: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021419s014lbl.pdf#page=12&amp;token=FdDYWusbnfzmikemm7imI1r8YckdMZevYb1sv1UmgwSKXEl2NaHx689KjNg3ffM6Ng8hbIyMzsKAttwICitHt1/RxiOUFwtPQsokBWE+lBlHdhKIFu17i+F2SzzCbI4/&amp;TOPIC_ID=9638\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021419s014lbl.pdf#page=12</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">QuilliChew ER: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207960s005lbl.pdf&amp;token=Ligr2U1U0E/RHuVGJJwk5B5txY7igO7FVl/k+zovh5obcLDHSZy4D8xsuZvhHIyQ2nuJJNI2ReOp7a/nCaO1jv4bhHulNyWVvZCkJ9gMERQ=&amp;TOPIC_ID=9638\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207960s005lbl.pdf</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Quillivant XR extended release oral suspension: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202100s012lbl.pdf#page=14&amp;token=sgue1VRxbi89Ggz7GyoGb0MijJLZRShfWEDLShT0Aaro3KEFPpYPjRfuLenD9FYaipXqrMxChtVeECes83gv8m/lrBINKl/TM/fclBrI2tqS8JOgyGMVd0pwg9iWfArC&amp;TOPIC_ID=9638\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/202100s012lbl.pdf#page=14</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ritalin: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/010187s087lbl.pdf#page=11&amp;token=7snEsWqzWWJm1cmXrT9zJgZi2suvoP9f5bnJSU0sqF3IH8tIvgnewKpx4nCaaiObA1EpQ3O3saJXorMy+dmmXqo4tsgfnyy/bLC/C5a8ARkFuwmYakeYByUTf3vsDplS&amp;TOPIC_ID=9638\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/010187s087lbl.pdf#page=11</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ritalin LA: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021284s034lbl.pdf#page=18&amp;token=PCHEU0as/LkGByUitDbhqIxUjegyZrtf+PiDNxDUj2jaOGqlT7sHW+8wFX9pI0cQ7pQzZfZlHJl6drYLILgXENcGM5WsB7woLecG65gL37SfJWaOKrbYyn1DE2fIwEra&amp;TOPIC_ID=9638\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021284s034lbl.pdf#page=18</a></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ritalin-SR: <a target=\"_blank\" href=\"http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018029s055lbl.pdf#page=14&amp;token=OgXmtwamnc1jOK0lgfAVTnlrfmQwLVB+kX1/f8y9/uKtc6C6uw2lQlgoBj03xQ7hsl37ssI/sC+O9AeyV6O+fkIp52AcrpEeybTXwFa+TNpsKb2kenu3p1tXWg9hRb+n&amp;TOPIC_ID=9638\" target=\"_blank\">http://www.accessdata.fda.gov/drugsatfda_docs/label/2017/018029s055lbl.pdf#page=14</a></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195275\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Controlled-release capsule (Biphentin, Foquest [Canadian products]): Administer in the morning. Swallow whole with full glass of water (Foquest) or with water or other liquid (Biphentin); do not crush or chew capsules. Alternatively, capsules may be opened and the contents sprinkled onto applesauce, ice cream, or yogurt, but the beads must not be crushed or chewed.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Foquest should be administered immediately after or within 10 minutes of sprinkling capsule contents on food; after administration patients should rinse their mouths with water and swallow. Discard if not administered within 10 minutes of mixing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release (IR) tablet (Ritalin), IR solution (Methylin), IR chewable tablet (Methylin): Administer each dose 30 to 45 minutes before a meal. Ensure last daily dose is administered before 6 pm if difficulty sleeping occurs. Administer chewable tablet with at least 8 ounces of water or other fluid.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release capsule (Aptensio XR, Metadate CD, Ritalin LA): Administer in the morning with or without food. Alternatively, capsules may be opened and the contents sprinkled onto a small amount (equal to 1 tablespoon) of cold applesauce. Swallow applesauce mixture immediately without chewing. Do not crush or chew capsule contents.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release orally disintegrating tablet (Cotempla XR-ODT): Administer in the morning consistently with or without food. Remove the tablet from blister pack with dry hands by peeling back (do not push tablet through foil), and administer immediately. Allow the tablet to dissolve on the tongue without chewing or crushing; no liquid is needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release suspension (Quillivant XR): Administer in the morning with or without food. Shake bottle &ge;10 seconds prior to administration. Use the oral dosing dispenser provided; wash after each use.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release chewable tablet (QuilliChew ER): Administer in the morning with or without food. Tablets are scored and may be halved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release tablet:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Metadate ER: Administer 30 to 45 minutes before a meal. Swallow whole with water or other fluid; do not crush or chew tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Concerta: Administer in the morning. May be taken with or without food, but must be taken with water or other fluid. Do not crush, chew, or divide tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sustained-release tablet (Ritalin-SR): Administer 30 to 45 minutes before a meal. Swallow whole; do not crush or chew tablet.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Topical: Transdermal (Daytrana): Apply to clean, dry, non-oily, intact skin to the hip area, avoiding the waistline; do not premedicate the patch site with hydrocortisone or other solutions, creams, ointments, or emollients. Apply at the same time each day to alternating hips. Press firmly for 30 seconds to ensure proper adherence. Avoid exposure of application site to external heat source, which may increase the amount of drug absorbed. If difficulty is experienced when separating the patch from the liner or if any medication (sticky substance) remains on the liner after separation; discard that patch and apply a new patch. Do not use a patch that has been damaged or torn; do not cut patch. If patch should dislodge, may replace with new patch (to different site) but total wear time should not exceed 9 hours; do not reapply with dressings, tape, or common adhesives. Patch may be removed early if a shorter duration of effect is desired or if late day side effects occur. Wash hands with soap and water after handling. Avoid touching the sticky side of the patch. If patch removal is difficult, an oil-based product (eg, petroleum jelly, olive oil) may be applied to the patch edges to aid removal; never apply acetone-based products (eg, nail polish remover) to patch. Dispose of used patch by folding adhesive side onto itself, and discard in toilet or appropriate lidded container.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195274\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Attention-deficit/hyperactivity disorder:</b> Treatment of attention-deficit/hyperactivity disorder (ADHD)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Narcolepsy:</b> Symptomatic management of narcolepsy (<b>except</b> Aptensio XR, Concerta, Cotempla XR-ODT, Daytrana, Metadate CD, Ritalin LA, QuilliChew ER, Quillivant XR, and Biphentin [Canadian product]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25469400\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Depression (terminal illness, palliative care); Fatigue, cancer related (adults); Major depressive disorder (antidepressant augmentation; geriatric patients)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195336\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate CD may be confused with Metadate ER</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Metadate ER may be confused with methadone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Methylphenidate may be confused with methadone</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">QuilliChew ER may be confused with Quillivant XR</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ritalin may be confused with Rifadin</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ritalin LA may be confused with Ritalin-SR</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195263\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (2% to 22%), insomnia (including initial insomnia; 2% to 13%), irritability (6% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Decreased appetite (2% to 26%), xerostomia (oral: 14%), nausea (2% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Tachycardia (oral: 5%; transdermal: &le;1%), palpitations (oral: 3%; transdermal: &lt;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Emotional lability (1% to 9%), anxiety (oral: 8%), tics (transdermal: 7%; oral: 2%), dizziness (2% to 7%), depressed mood (oral: 4%), nervousness (oral: 3%; transdermal: &lt;1%), restlessness (oral: 3%), aggressive behavior (oral: 2%), agitation (oral: 2%), depression (&le;2%), hypertonia (oral: 2%), lack of emotion (oral: 2%), vertigo (oral: 2%), confusion (oral: 1%), sedation (oral: 1%), tension (oral: 1%), tension headache (oral: 1%), paresthesia (&le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Hyperhidrosis (oral: 5%), excoriation (oral: 4%), skin rash (oral: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Weight loss (2% to 9%), decreased libido (oral: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (transdermal: 10%; oral: 2% to 3%), abdominal pain (transdermal: 5% to 7%), upper abdominal pain (oral: 6%), anorexia (2% to 5%), bruxism (oral: 2%), dyspepsia (oral: 2%), motion sickness (oral: 2%), constipation (oral: 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Tremor (oral: 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Blurred vision (&le;2%), eye pain (oral: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Nasopharyngitis (oral: 3%), cough (oral: 2%), upper respiratory tract infection (oral: 2%), oropharyngeal pain (oral: 1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (oral: 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac arrhythmia, decreased blood pressure, decreased pulse, heart murmur, hypertension, increased pulse</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Gilles de la Tourette syndrome (rare), hypervigilance, jitteriness, mood changes, outbursts of anger, panic attack, psychomotor agitation, sleep disorder, toxic psychosis</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Macular eruption</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Growth suppression, hot flash, increased thirst</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal distress, diarrhea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Erectile dysfunction</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia, leukopenia</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum ALT</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle spasm, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Dry eye syndrome</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Dyspnea, sinusitis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Accommodation disturbance, allergic contact dermatitis, allergic contact sensitivity, alopecia, angina pectoris, application site reaction, arthralgia, auditory hallucination, bradycardia, cerebral arteritis, cerebrovascular occlusion, change in libido, change in WBC count, chest discomfort, chest pain, decreased platelet count, decreased therapeutic response, diplopia, disorientation, drowsiness, dyskinesia, erythema, extrasystoles, fatigue, hallucination, hepatic failure (acute), hepatic injury (severe), hyperpyrexia, hypersensitivity reaction (including angioedema, anaphylaxis, auricular swelling, bullous conditions, exfoliative dermatitis, erythema multiforme with histopathological findings of necrotizing vasculitis, pruritus), immune thrombocytopenia, increased blood pressure, increased heart rate, increased liver enzymes, increased serum alkaline phosphatase, increased serum bilirubin, lethargy, leukoderma (chemical; FDA Safety Alert 2015), loss of scalp hair, mania, muscle twitching, myalgia, mydriasis, neuroleptic malignant syndrome, pancytopenia, peripheral vascular insufficiency, priapism, Raynaud phenomenon, rhabdomyolysis, seizure, supraventricular tachycardia, talkativeness, thrombocytopenia, thrombotic thrombocytopenic purpura, tonic-clonic seizures, urticaria, ventricular premature contractions, visual disturbance, visual hallucination</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195278\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>US labeling:</i> Hypersensitivity (eg, angioedema, anaphylaxis) to methylphenidate or any component of the formulation; use during or within 14 days following MAO inhibitor therapy; marked anxiety, tension, and agitation (excluding Aptensio XR, Cotempla XR-ODT, QuilliChew ER, and Quillivant XR); glaucoma (excluding Aptensio XR, Cotempla XR-ODT, QuilliChew ER, and Quillivant XR); family history or diagnosis of Tourette syndrome or tics (excluding Aptensio XR, Cotempla XR-ODT, QuilliChew ER, and Quillivant XR)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Additional contraindications: Metadate CD: Severe hypertension, heart failure, arrhythmia, hyperthyroidism or thyrotoxicosis, recent MI or angina; concomitant use of halogenated anesthetics; patients with rare hereditary problems of fructose intolerance, glucose-galactose malabsorption, or sucrose-isomaltase insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to methylphenidate or any component of the formulation; marked anxiety, tension, and agitation; glaucoma; use during or within 14 days following MAO inhibitor therapy; family history or diagnosis of Tourette syndrome or tics (excluding Concerta), thyrotoxicosis, advanced arteriosclerosis, symptomatic cardiovascular disease, or moderate to severe hypertension</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Additional contraindications:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Foquest: Known hypersensitivity or idiosyncrasy to sympathomimetic amines; history of drug abuse</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ritalin and Ritalin SR: Pheochromocytoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195260\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular events: CNS stimulant use has been associated with serious cardiovascular events (eg, sudden death, arrhythmia, and myocardial infarction in children and adolescents; sudden death, stroke, and myocardial infarction in adults) in patients with and without preexisting structural cardiac abnormalities or other serious heart problems (Shin 2016). These products should be avoided in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that could further increase their risk of sudden death. Patients should be carefully evaluated for cardiac disease prior to initiation of therapy. Some products are contraindicated in patients with heart failure, arrhythmias or recent MI.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Chemical leukoderma: Transdermal system may cause a persistent loss of skin pigmentation at and around the application site, as well as at distant sites from the application site; loss of skin pigmentation may continue after discontinuation of transdermal system. May resemble vitiligo especially if loss of skin pigmentation occurs at areas distant from application site; use with caution in patients with a history and/or family history of vitiligo. Monitor for signs of skin depigmentation; immediately discontinue use if patient experiences chemical leukoderma.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions, such as angioedema and anaphylactic reactions have been reported.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Peripheral vasculopathy: Stimulants are associated with peripheral vasculopathy, including Raynaud phenomenon; signs/symptoms are usually mild and intermittent, and generally improve with dose reduction or discontinuation. Digital ulceration and/or soft tissue breakdown have been observed rarely; monitor for digital changes during therapy and seek further evaluation (eg, rheumatology) if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Priapism: Prolonged and painful erections (priapism), sometimes requiring surgical intervention, have been reported (rarely) with methylphenidate and atomoxetine use in pediatric and adult patients. Priapism has been reported to develop after some time on the drug, often subsequent to an increase in dose but also during a period of drug withdrawal (drug holidays or discontinuation). Patients with certain hematological dyscrasias (eg, sickle cell disease), malignancies, perineal trauma, or concomitant use of alcohol, illicit drugs, or other medications associated with priapism may be at increased risk. Patients who develop abnormally sustained or frequent and painful erections should discontinue therapy and seek immediate medical attention. An emergent urological consultation should be obtained in severe cases. Priapism has been associated with different dosage forms and products; it is not known if rechallenge with a different formulation will risk recurrence. Avoidance of stimulants and atomoxetine may be preferred in patients with severe cases that were slow to resolve and/or required detumescence (Eiland 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Visual disturbance: Difficulty in accommodation and blurred vision have been reported with the use of stimulants.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Abuse potential: <b>[US Boxed Warning]: CNS </b><b>stimulants, including methylphenidate-containing products and amphetamines, have a high potential for abuse and dependence. Assess the risk of abuse prior to prescribing, and monitor for signs of abuse and dependence while on therapy. Long-term abusive use can lead to marked tolerance and psychological dependence with varying degrees of abnormal behavior. Frank psychotic episodes can occur, especially with parenteral abuse. Careful supervision is required during withdrawal from abusive use because severe depression may occur. Withdrawal following long-term therapeutic use may unmask symptoms of the underlying disorder that may require follow-up. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Cardiovascular disorders: Use with caution in patients with hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate. Some products are contraindicated in patients with severe hypertension, hyperthyroidism or angina.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Psychiatric disorders: Use with caution in patients with pre-existing psychosis or bipolar disorder (may induce mixed/manic episode). May exacerbate symptoms of behavior and thought disorder in psychotic patients; new-onset psychosis or mania may occur with stimulant use. Patients should be screened for bipolar disorder prior to treatment; consider discontinuation if such symptoms (eg, delusional thinking, hallucinations, mania) occur. May be associated with aggressive behavior or hostility (causal relationship not established); monitor for development or worsening of these behaviors. Suicidal ideation, attempts, and very rarely, completed suicide have been reported. Monitor for suicide-related behavior.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizure disorder: Use with caution in patients with a history of seizure disorder; may lower seizure threshold leading to new onset or breakthrough seizure activity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Tourette syndrome/tics: Use with caution in patients with Tourette syndrome or other tic disorders. Stimulants may exacerbate tics (motor and phonic) and Tourette syndrome; however, evidence demonstrating increased tics is limited. Evaluate for tics and Tourette syndrome prior to therapy initiation; use is contraindicated with some products (AACAP [Murphy 2013; Pliszka 2007]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Appetite suppression may occur, particularly in children. Use of stimulants has been associated with weight loss and slowing of growth rate; monitor growth rate and weight during treatment. Treatment interruption may be necessary in patients who are not increasing in height or gaining weight as expected.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Biphentin, Foquest [Canadian products]: Controlled-release capsules are not interchangeable with other controlled-release formulations.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Concerta: Should not be used with preexisting severe gastrointestinal narrowing conditions, such as esophageal motility disorders, small bowel disease, &ldquo;short&rdquo; gut syndrome, cystic fibrosis, history of peritonitis, chronic intestinal pseudo-obstruction, or Meckel diverticulum.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Daytrana: Transdermal system may cause allergic contact sensitization, characterized by intense local reactions (eg, edema, papules) that may spread beyond the patch site; sensitization may subsequently manifest systemically with other routes of methylphenidate administration; monitor closely. Avoid exposure of application site to any direct external heat sources (eg, hair dryers, heating pads, electric blankets); may increase the rate and extent of absorption and risk of overdose. Efficacy of therapy for &gt;7 weeks has not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Lactose/sucrose: Some dosage forms may contain lactose or sucrose; use with caution in patients intolerant to either component (some manufacturer labels recommend avoiding use in such patients).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Metadate CD: Concomitant use with halogenated anesthetics is contraindicated; may cause sudden elevations in blood pressure; if surgery is planned, do not administer Metadate CD on the day of surgery.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Phenylketonuria: Some dosage forms contain phenylalanine, which can be harmful to patients with phenylketonuria (PKU). Before prescribing, consider the combined daily amount of phenylalanine from all sources.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; ADHD treatment: Appropriate use: Recommended to be used as part of a comprehensive treatment program for attention deficit disorders.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195323\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195265\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9638&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acebrophylline: May enhance the stimulatory effect of CNS Stimulants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): May enhance the adverse/toxic effect of Methylphenidate. Alcohol (Ethyl) may increase the serum concentration of Methylphenidate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antacids: May increase the absorption of Methylphenidate. Specifically, antacids may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antihypertensive Agents: Methylphenidate may diminish the antihypertensive effect of Antihypertensive Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anti-Parkinson Agents (Dopamine Agonist): Methylphenidate may enhance the adverse/toxic effect of Anti-Parkinson Agents (Dopamine Agonist). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents: May enhance the adverse/toxic effect of Methylphenidate. Methylphenidate may enhance the adverse/toxic effect of Antipsychotic Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BuPROPion: May enhance the neuroexcitatory and/or seizure-potentiating effect of Agents With Seizure Threshold Lowering Potential.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cannabinoid-Containing Products: May enhance the tachycardic effect of Sympathomimetics.<b> Exceptions: </b>Cannabidiol.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloNIDine: Methylphenidate may enhance the adverse/toxic effect of CloNIDine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cocaine (Topical): May enhance the hypertensive effect of Sympathomimetics. Management: Consider alternatives to use of this combination when possible. Monitor closely for substantially increased blood pressure or heart rate and for any evidence of myocardial ischemia with concurrent use.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Doxofylline: Sympathomimetics may enhance the adverse/toxic effect of Doxofylline. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: Methylphenidate may increase the serum concentration of Fosphenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Guanethidine: May enhance the arrhythmogenic effect of Sympathomimetics. Guanethidine may enhance the hypertensive effect of Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Histamine H2 Receptor Antagonists: May increase the absorption of Methylphenidate. Specifically, H2-antagonists may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Inhalational Anesthetics: Methylphenidate may enhance the hypertensive effect of Inhalational Anesthetics. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ioflupane I 123: Methylphenidate may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iohexol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iohexol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iohexol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iomeprol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iomeprol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iomeprol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Iopamidol: Agents With Seizure Threshold Lowering Potential may enhance the adverse/toxic effect of Iopamidol. Specifically, the risk for seizures may be increased.  Management: Discontinue agents that may lower the seizure threshold 48 hours prior to intrathecal use of iopamidol. Wait at least 24 hours after the procedure to resume such agents. In nonelective procedures, consider use of prophylactic anticonvulsants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Monoamine Oxidase Inhibitors: May enhance the hypertensive effect of Methylphenidate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PHENobarbital: Methylphenidate may increase the serum concentration of PHENobarbital. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: Methylphenidate may increase the serum concentration of Phenytoin. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Primidone: Methylphenidate may increase serum concentrations of the active metabolite(s) of Primidone. Specifically, phenobarbital concentrations could become elevated. Methylphenidate may increase the serum concentration of Primidone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Proton Pump Inhibitors: May increase the absorption of Methylphenidate. Specifically, proton pump inhibitors may interfere with the normal release of drug from the extended-release capsules (Ritalin LA brand), which could result in both increased absorption (early) and decreased delayed absorption.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Serotonin Modulators: Methylphenidate may enhance the adverse/toxic effect of Serotonin Modulators. Specifically, the risk of serotonin syndrome or serotonin toxicity may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tricyclic Antidepressants: Methylphenidate may enhance the adverse/toxic effect of Tricyclic Antidepressants. Methylphenidate may increase the serum concentration of Tricyclic Antidepressants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Methylphenidate may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195292\" class=\"block foi drugH1Div\"><span class=\"drugH1\">Food Interactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ethanol: Alcohol consumption increases the rate of methylphenidate release from Metadate CD (extended-release capsules), Ritalin LA (extended-release capsules), and QuilliChew ER (extended-release chewable tablet), but not from Concerta (extended-release tablet); an <i>in vitro</i> study involving Metadate CD and Ritalin LA showed that an alcohol concentration of 40% resulted in 84% and 98% of the methylphenidate being released in the first hour, respectively; a study involving QuilliChew ER showed that an alcohol concentration of 40% resulted in 90% of the methylphenidate being released in the first hour. Management: Avoid consuming alcohol during therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Food: Food may increase oral absorption of immediate-release tablet/solution/chewable tablet. Management: Administer 30 to 45 minutes before meals.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195267\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195281\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Information related to the use of methylphenidate in pregnant women with attention-deficit/hyperactivity disorder (Bolea-Alamanac 2014; Dideriksen 2013) or narcolepsy (Maurovich-Horvat 2013; Thorpy 2013) is limited. If treatment of ADHD in pregnancy is needed, methylphenidate may be considered (Larsen 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3277308\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methylphenidate is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The relative infant dose (RID) of methylphenidate is 0.7% when calculated using the highest breast milk concentration located and compared to a weight-adjusted maternal dose of 52 mg/day.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000). However some sources note breastfeeding should only be considered if the RID is &lt;5% for psychotropic agents (Larsen 2015).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">The RID of methylphenidate was calculated using a milk concentration of 19 mcg/L, providing an absolute daily infant dose via breast milk of 2.9 mcg/kg/day. This milk concentration was obtained following maternal administration methylphenidate to three women for ADHD. Maternal doses ranged from 35 to 80 mg/day (Hackett 2006). Authors of two additional case reports calculated the RID of methylphenidate &lt;1% (Hackett 2006; Spigset 2007). In a case report, methylphenidate was no longer detectable in breast milk 20 to 21 hours after the maternal dose following administration of the immediate release tablet (Spigset 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adverse events were not noted in three case reports (Bolea-Alamanac 2014; Hackett 2006; Spigset 2007); however, infants in two cases were older (6 months of age and 11 months of age) and exposure was limited (Hackett 2006; Spigset 2007). Long-term developmental effects have not been studied. Growth and medical development were normal in one child up to 1 year of age (Bolea-Alamanac 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of exposure to the infant and the benefits of treatment to the mother. Monitor breastfeeding infants for adverse reactions, such as agitation, anorexia, insomnia, and reduced weight gain.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195282\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Administer immediate release (IR) tablet (Ritalin), IR solution (Methylin), IR chewable tablet (Methylin), and sustained released tablet (Ritalin-SR) 30-45 minutes before meals. Some products may contain phenylalanine.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195269\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Periodic CBC, differential, and platelet counts with prolonged use; blood pressure, heart rate; signs and symptoms of depression, aggression, hostility, suicidal behavior/ideation; growth rate in children; signs of central nervous system stimulation; signs of peripheral vasculopathy (eg, digital changes)</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Transdermal: Signs of worsening erythema, blistering or edema which does not improve within 48 hours of patch removal, or spreads beyond patch site.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">When used for the treatment of ADHD, thoroughly evaluate for cardiovascular risk. Monitor heart rate, blood pressure, and consider obtaining ECG prior to initiation (Vetter 2008).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195259\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Mild CNS stimulant; blocks the reuptake of norepinephrine and dopamine into presynaptic neurons; appears to stimulate the cerebral cortex and subcortical structures similar to amphetamines </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195277\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action (AAP 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Immediate-release formulations (chewable tablet, oral solution, tablet [Methylin, Ritalin]): 20 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Extended-release formulations (capsule [Metadate CD, Ritalin LA], tablets [Concerta]): 20 to 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Sustained-release tablet (Ritalin-SR): 60 to 180 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Transdermal (Daytrana): 60 minutes</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Oral: Controlled-release: Foquest [Canadian product]: Within 1 hour</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Maximum effect: Oral: Immediate-release tablet: Within 2 hours; Sustained-release tablet: Within 4 to 7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration of action:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate-release formulations (chewable tablet, oral solution, immediate-release tablet [Methylin, Ritalin]): 3 to 5 hours (AAP 2011; Jain 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release capsule: Metadate CD, Ritalin LA: 6 to 8 hours (AAP 2011); Aptensio XR: &le;16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release tablet (Concerta): 8 to 12 hours (AAP 2011; Jain 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Sustained-release tablet (Ritalin-SR): 2 to 8 hours (AAP 2011; Jain 2017)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Controlled-release capsule (Foquest [Canadian product]): 16 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal (Daytrana): 11 to 12 hours (AAP 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Oral: Readily absorbed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate-release chewable tablet: Methylin: A high-fat meal delayed peak time (~1 hour) and increased AUC (~20%).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Controlled-release capsule:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Biphentin [Canadian product]: Food delayed initial peak slightly (~18 minutes); relative to immediate-release tablets, AUC is similar in fed or fasted state (~100%)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Foquest [Canadian product]: Food does not significantly affect AUC and C<sub>max</sub></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release capsule:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Aptensio XR: A high-fat meal increased C<sub>max</sub> (~28%) and AUC (~19%). At an alcohol concentration up to 40% there was 96% release of methylphenidate within 2 hours.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Metadate CD: A high-fat meal delayed the early peak (~1 hour), and increased C<sub>max</sub> (~30%) and AUC (~17%). At an alcohol concentration of 40%, there was an increase in the release rate of methylphenidate in the first hour, resulting in 84% of the methylphenidate being released.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Ritalin LA: A high-fat meal delayed absorption and peak times, but not the amount absorbed nor initial peak concentration (second peak lowered by ~25%). At an alcohol concentration of 40%, there was a 98% release of methylphenidate in the first hour.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release chewable tablet: A high-fat meal increased C<sub>max</sub> (~20%) and AUC<sub>inf</sub> (~4%). At an alcohol concentration of 40%, there was an increase in the release rate of methylphenidate in the first hour, resulting in 90% of the methylphenidate being released.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release orally disintegrating tablet: Cotempla XR-ODT: A high-fat meal decreased C<sub>max</sub> (24%) and increased AUC<sub>inf </sub>(16%) and led to an earlier peak (~0.5 hour).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release suspension: Quillivant XR: A high-fat meal led to an earlier peak (~1 hour), and increased C<sub>max</sub> (~28%) and AUC (~19%).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Extended-release tablet: Metadate ER: Food resulted in greater C<sub>max</sub> and AUC compared to fasting.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Immediate-release solution: Methylin: A high-fat meal delayed peak time (~1 hour), and increased C<sub>max</sub> (~13%) and AUC (~25%).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal: Absorption increased when applied to inflamed skin or exposed to heat. Absorption is continuous for 9 hours after application.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>d</sub>: <i>d</i>-methylphenidate: 2.65 &plusmn; 1.11 L/kg, <i>l</i>-methylphenidate: 1.80 &plusmn; 0.91 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 10% to 33%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Extensive metabolism, predominately via de-esterification by carboxylesterase CES1A1 to alpha-phenyl-piperidine acetic acid (PPAA; ritalinic acid) which has little to no pharmacologic activity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bioavailability:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release chewable tablets and oral solution: Bioequivalent to immediate-release tablets</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended release capsule: Aptensio XR: 102% (relative to immediate release oral product)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release suspension: Quillivant XR: 95% (relative to immediate release oral solution)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal patch (Daytrana): Lower first-pass effect compared to oral administration; thus, much lower doses (on a mg/kg basis) given via the transdermal route may still produce higher AUCs, compared to the oral route</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release chewable tablet: Methylin: Adults: 3 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Controlled-release capsule: Biphentin [Canadian product]: Children: 2.4 hours; Adults: 2.1 hours; Foquest [Canadian product]: Adults: 6.95 &plusmn; 3.25 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release capsule:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Aptensio XR: Adults: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Metadate CD: Adults: 6.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ritalin LA: Children: ~2.45 hours (range: 1.5 to 4 hours); Adults: ~3.3 hours (range: 3 to 4.2 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release chewable tablets: ~5.2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release orally disintegrating tablet: 4 to 4.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release suspension: Quillivant XR: Children &ge;9 years, Adolescents, and Adults: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release tablet: Concerta: Adolescents and Adults: ~3.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release solution: Methylin: Adults: 2.7 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release tablet: Adults: 2.8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal: Children and Adolescents 6 to 17 years: <i>d</i>-methylphenidate ~4 to 5 hours, <i>l</i>-methylphenidate 1.4 to 2.9 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Time to peak:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release chewable tablet: Methylin: ~1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release chewable tablet: QuilliChew ER: 5 hours (median)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Controlled-release capsule:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Biphentin [Canadian product]: Children: Initial: ~2.5 hours; Adults: Initial: ~2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Foquest [Canadian product]: Adults: Initial peak at ~1.6 hours followed by second peak at ~12.5 hours (range: 11 to 16 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release capsule:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Aptensio XR: Adults: Initial: ~2 hours; Second peak: ~8 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Metadate CD: Children: Initial: ~1.5 hours; Second peak: ~4.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Ritalin LA:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Children: Initial: 1 to 3 hours; Second peak: 5 to 11 hour</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adults: Initial: 1.3 to 4 hours; Second peak: 4.3 to 6.5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release orally disintegrating tablet: Cotempla XR-ODT: ~5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release suspension: Quillivant XR: Children (9 to 12 years): 4.05 hours (range: 3.98 to 6 hours); Adolescents (13 to 15 years): 2 hours (range: 1.98 to 4 hours); Adults: 4 hours (range: 1.3 to 7.3 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Extended-release tablet: Concerta: Initial: ~1 hours, followed by gradually ascending concentrations over 5 to 9 hours; Mean peak: 6 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release solution: Methylin: 1 to 2 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Immediate-release tablet: Children: 1.9 hours (range: 0.3 to 4.4 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sustained-release tablet: Children: 4.7 hours (range: 1.3 to 8.2 hours)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Transdermal: ~8 to 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Urine (90% as metabolites and unchanged drug); Feces (1% to 3%)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5989423\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Aptensio XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (90): $772.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg (90): $772.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (90): $772.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (90): $772.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (90): $772.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (90): $772.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (90): $772.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Methylphenidate HCl ER (LA) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $1,027.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $567.43</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $580.34</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $596.46</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (30): $371.11</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule ER 24 Hour Therapy Pack</b> (Ritalin LA Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $1,194.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $1,194.20</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,221.40</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $1,255.32</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Capsule, controlled release</b> (Methylphenidate HCl ER (CD) Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $560.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $560.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $560.21</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $768.44</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">50 mg (100): $944.19</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">60 mg (100): $944.19</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Methylphenidate HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2.5 mg (100): $315.65</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $450.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $642.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (Daytrana Transdermal)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/9 hrs (30): $399.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">15 mg/9 hrs (30): $399.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/9 hrs (30): $399.77</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/9 hrs (30): $399.77</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Methylin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (500 mL): $84.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/5 mL (500 mL): $120.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Methylphenidate HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (500 mL): $451.61</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/5 mL (500 mL): $643.82</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension (reconstituted)</b> (Quillivant XR Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/5 mL (120 mL): $328.44</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Chewable Extended Release</b> (QuilliChew ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $1,286.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg (100): $1,286.29</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">40 mg (100): $1,286.29</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet Extended Release Dispersible</b> (Cotempla XR-ODT Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8.6 mg (30): $383.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">17.3 mg (30): $383.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25.9 mg (30): $383.72</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, 24-hour</b> (Methylphenidate HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18 mg (100): $622.18</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">27 mg (100): $637.78</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">36 mg (100): $657.86</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">54 mg (100): $715.83</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Concerta Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18 mg (100): $1,306.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">27 mg (100): $1,339.56</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">36 mg (100): $1,381.80</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">54 mg (100): $1,503.60</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Metadate ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $216.73</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablet, controlled release</b> (Methylphenidate HCl ER Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $750.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">18 mg (100): $973.06</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $775.00</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">27 mg (100): $997.45</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">36 mg (100): $1,028.85</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">54 mg (100): $1,119.50</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">72 mg (100): $2,280.59</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Methylphenidate HCl Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $73.90</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $105.30</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $151.25</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Tablets</b> (Ritalin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg (100): $78.83</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (100): $112.38</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg (100): $161.59</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F195283\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Adaphen (ZA);</li>\n      <li>Adaphen XL (ZA);</li>\n      <li>Addwize (IN);</li>\n      <li>Aradix Retard (CL, PE, PY);</li>\n      <li>Artige (AU);</li>\n      <li>Attenta (AU);</li>\n      <li>Aurium (PY);</li>\n      <li>Cognil (PY);</li>\n      <li>Comcerta (VE);</li>\n      <li>Concentra (BD);</li>\n      <li>Concentra SR (BD);</li>\n      <li>Concerta (AE, AR, AT, AU, BB, BE, BG, BH, BM, BR, BS, BZ, CH, CL, CN, CO, CR, CY, DE, DK, DO, EC, EE, ES, FI, GR, GT, GY, HK, HN, HR, ID, IE, IL, IS, JM, JP, KW, LB, LT, LU, MT, MX, MY, NI, NL, NO, NZ, PA, PE, PH, PL, PR, PT, QA, RO, SA, SE, SG, SI, SK, SR, SV, TH, TR, TT, TW, UY, VN, ZW);</li>\n      <li>Concerta LP (FR);</li>\n      <li>Concerta Oros (KR);</li>\n      <li>Concerta XL (GB);</li>\n      <li>Equasym (BE, CH, ES, IE);</li>\n      <li>Equasym Depot (DK, NO, SE);</li>\n      <li>Equasym Retard (DE);</li>\n      <li>Equasym XL (GB);</li>\n      <li>Inspiral (IN);</li>\n      <li>Kontserta (UA);</li>\n      <li>Matoride XL (GB);</li>\n      <li>Medikinet (BE, CH, DE, DK, EE, GB, IE, NO, PL, SE);</li>\n      <li>Medikinet CR (DE);</li>\n      <li>Medikinet MR (IL, SG);</li>\n      <li>Medikinet Retard (KR);</li>\n      <li>Medikinet XL (EE, GB);</li>\n      <li>Metadate CD SR (KR);</li>\n      <li>Methylin (AR);</li>\n      <li>Methylphen (BD);</li>\n      <li>Metidate (IE);</li>\n      <li>MFD (AR);</li>\n      <li>Nebapul (CL);</li>\n      <li>Penid (KR);</li>\n      <li>Phenida (PK);</li>\n      <li>Prohiper (ID);</li>\n      <li>Quasym LP (FR);</li>\n      <li>Rilatine (LU);</li>\n      <li>Ritalin (AE, AT, AU, BB, BF, BH, BJ, CH, CI, CL, CO, CY, CZ, DE, DK, EG, ET, GB, GH, GM, GN, HK, ID, IE, IL, IQ, IR, IS, JO, JP, KE, KW, LB, LK, LR, LY, MA, ML, MR, MT, MU, MW, MX, MY, NE, NG, NO, NZ, OM, PE, PK, QA, SA, SC, SD, SE, SG, SI, SL, SN, SY, TN, TW, TZ, UG, VE, YE, ZM, ZW);</li>\n      <li>Ritalin LA (AU, BB, CO, HK, ID, IL, MY, PE, PT, TR);</li>\n      <li>Ritalin LP (VE);</li>\n      <li>Ritalin SR (NO, VE);</li>\n      <li>Ritalin-SR (CH, HK, ID, MY, NZ, SG);</li>\n      <li>Ritalina (AR, BR, PY, UY);</li>\n      <li>Ritalina LA (BR, UY);</li>\n      <li>Ritaline (BE, FR, GR);</li>\n      <li>Ritaline LP (FR);</li>\n      <li>Rubifen (AR, ES, LK, MY, NZ, PT, SG, TH, UY);</li>\n      <li>Rubifen SR (NZ);</li>\n      <li>Tradea (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Tradea LP (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Xenidate XL (GB)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. <i>Pediatrics.</i> 2011;128(5):1007-1022. doi: 10.1542/peds.2011-2654.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/22003063/pubmed\" target=\"_blank\" id=\"22003063\">22003063</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Geriatrics Society 2012 Beers Criteria Update Expert Panel, &quot;American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,&quot; <i>J Am Geriatr Soc</i>, 2012, 60(4):616-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/22376048/pubmed\" target=\"_blank\" id=\"22376048\">22376048</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/27060684/pubmed\" target=\"_blank\" id=\"27060684\">27060684</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aptensio XR (methylphenidate) extended-release capsules [prescribing information]. Greenville, NC: Patheon; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arnold LE, Lindsay RL, L&oacute;pez FA, et al, &quot;Treating Attention-Deficit/Hyperactivity Disorder With a Stimulant Transdermal Patch: The Clinical Art,&quot; <i>Pediatrics</i>, 2007, 120(5):1100-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/17974748/pubmed\" target=\"_blank\" id=\"17974748\">17974748</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biphentin (methylphenidate) [product monograph]. Pickering, Ontario, Canada: Purdue Pharma; April 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bolea-Alamanac BM, Green A, Verma G, Maxwell P, Davies SJ. Methylphenidate use in pregnancy and lactation: a systematic review of evidence. <i>Br J Clin Pharmacol</i>. 2014;77(1):96-101.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/23593966/pubmed\" target=\"_blank\" id=\"23593966\">23593966</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bond WS, &ldquo;Recognition and Treatment of Attention Deficit Disorder,&rdquo; <i>Clin Pharm</i>, 1987, 6(8):617-24.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/2891464/pubmed\" target=\"_blank\" id=\"2891464\">2891464</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bower JE, Bak K, Berger A, et al; American Society of Clinical Oncology. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation.<i> J Clin Oncol</i>. 2014;32(17):1840-1850.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/24733803/pubmed\" target=\"_blank\" id=\"24733803\">24733803</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Concerta (methylphenidate) [prescribing information]. Titusville, NJ: Janssen; January 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Concerta (methylphenidate) [product monograph]. Toronto, Ontario, Canada: Janssen Inc; October 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cooper WO, Habel LA, Sox CM, et al, &ldquo;ADHD Drugs and Serious Cardiovascular Events in Children and Young Adults,&rdquo; <i>N Engl J Med</i>, 2011, 365(20):1896-904.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/22043968/pubmed\" target=\"_blank\" id=\"22043968\">22043968</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cotempla XR-ODT (methylphenidate) [prescribing information]. Grand Prairie, TX: Neos Therapeutics Brands, LLC; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Daytrana (methylphenidate) [prescribing information]. Miami, FL: Noven; November 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dideriksen D, Potteg&aring;rd A, Hallas J, et al, &quot;First Trimester <i>in utero</i> Exposure to Methylphenidate,&quot; <i>Basic Clin Pharmacol Toxicol</i>, 2013, 112(2):73-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/23136875/pubmed\" target=\"_blank\" id=\"23136875\">23136875</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Eiland LS, Bell EA, Erramouspe J. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children. <i>Ann Pharmacother</i>. 2014;48(10):1350-1355.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/24982313/pubmed\" target=\"_blank\" id=\"24982313\">24982313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    FDA Safety Alert. Daytrana Patch (methylphenidate). Food and Drug Administration website. http://www.fda.gov/Drugs/DrugSafety/ucm452244.htm.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foquest (methylphenidate) [product monograph]. Pickering, Ontario, Canada: Purdue Pharma; December 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fratto G, Manzon L. Use of psychotropic drugs and associated dental diseases. <i>Int J Psychiatry Med.</i> 2014;48(3):185-197.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/25492713/pubmed\" target=\"_blank\" id=\"25492713\">25492713</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Greenhill LL, &ldquo;Pharmacologic Treatment of Attention Deficit Hyperactivity Disorder,&rdquo; <i>Psychiatr Clin North Am</i>, 1992, 15(1):1-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/1347936/pubmed\" target=\"_blank\" id=\"1347936\">1347936</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habel LA, Cooper WO, Sox CM, et al, &ldquo;ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-Aged Adults,&rdquo; 2011, <i>JAMA</i>, 306(24):2673-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/22161946/pubmed\" target=\"_blank\" id=\"22161946\">22161946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. <i>JAMA</i>. 2011;306(24):2673-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/22161946/pubmed\" target=\"_blank\" id=\"22161946\">22161946</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hackett LP, Kristensen JH, Hale TW, et al, &ldquo;Methylphenidate and Breast-Feeding,&rdquo; <i>Ann Pharmacother</i>, 2006, 40(10):1890-1.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/16940409/pubmed\" target=\"_blank\" id=\"16940409\">16940409</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19281939\"></a>Hardy SE. Methylphenidate for treatment of depressive symptoms, including fatigue and apathy, in medically ill older adults and terminally ill adults. <i>Am J Geriatr Pharmacother</i>. 2009;7(1):34-59.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/19281939/pubmed\" target=\"_blank\" id=\"19281939\">19281939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11712722\"></a>Homsi J, Nelson KA, Sarhill N, et al. A phase II study of methylphenidate for depression in advanced cancer. <i>Am J Hosp Palliat Care</i>. 2001;18(6):403-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/11712722/pubmed\" target=\"_blank\" id=\"11712722\">11712722</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/10891521/pubmed\" target=\"_blank\" id=\"10891521\">10891521</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jain R, Jain S, Montano CB. Addressing diagnosis and treatment gaps in adults with attention-deficit/hyperactivity disorder. <i>Prim Care Companion CNS Disord. </i>2017;19(5). pii: 17nr02153. doi: 10.4088/PCC.17nr02153.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/28906602/pubmed\" target=\"_blank\" id=\"28906602\">28906602</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kelly DP and Aylward GP, &ldquo;Attention Deficits in School-Aged Children and Adolescents,&rdquo; <i>Pediatr Clin North Am</i>, 1992, 39(3):487-512.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/1574355/pubmed\" target=\"_blank\" id=\"1574355\">1574355</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"22208450\"></a>Kerr CW, Drake J, Milch RA, et al. Effects of methylphenidate on fatigue and depression: a randomized, double-blind, placebo-controlled trial. <i>J Pain Symptom Manage</i>. 2012;43(1):68-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/22208450/pubmed\" target=\"_blank\" id=\"22208450\">22208450</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/26344706/pubmed\" target=\"_blank\" id=\"26344706\">26344706</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16473984\"></a>Lavretsky H, Park S, Siddarth P, Kumar A, Reynolds CF 3rd. Methylphenidate-enhanced antidepressant response to citalopram in the elderly: a double-blind, placebo-controlled pilot trial. <i>Am J Geriatr Psychiatry</i>. 2006;14(2):181-185.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/16473984/pubmed\" target=\"_blank\" id=\"16473984\">16473984</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"25677354\"></a>Lavretsky H, Reinlieb M, St Cyr N, Siddarth P, Ercoli LM, Senturk D. Citalopram, methylphenidate, or their combination in geriatric depression: a randomized, double-blind, placebo-controlled trial. <i>Am J Psychiatry</i>. 2015;172(6):561-569.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/25677354/pubmed\" target=\"_blank\" id=\"25677354\">25677354</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lazarus LW, Moberg PJ, Langsley PR, et al, &ldquo;Methylphenidate and Nortriptyline in the Treatment of Poststroke Depression: A Retrospective Comparison,&rdquo; <i>Arch Phys Med Rehabil</i>, 1994, 75(4):403-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/8172499/pubmed\" target=\"_blank\" id=\"8172499\">8172499</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Manzi S, Law T, Shannon MW, et al, &ldquo;Methylphenidate Produces a False-Positive Urine Amphetamine Screen,&rdquo; <i>Pediatr Emerg Care</i>, 2002, 18(5):401.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/12395015/pubmed\" target=\"_blank\" id=\"12395015\">12395015</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maurovich-Horvat E, Kemlink D, H&ouml;gl B, et al, &quot;Narcolepsy and Pregnancy: A Retrospective European Evaluation of 249 Pregnancies,&quot; <i>J Sleep Res</i>, 2013, doi: 10.1111/jsr.12047.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/23560595/pubmed\" target=\"_blank\" id=\"23560595\">23560595</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metadate CD (methylphenidate) [prescribing information]. Rochester, NY: UCB Inc; February 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Metadate ER (methylphenidate) [prescribing information]. Smyrna, GA: UCB, Inc; February 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Methylin chewable tablets [prescribing information]. Florham Park, NJ: Shionogi Inc; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Methylin oral solution [prescribing information]. Florham Park, NJ: Shionogi Inc; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Modi NB, Lindemulder B, and Gupta SK, &ldquo; Single- and Multiple-Dose Pharmacokinetics of an Oral Once-a-day Osmotic Controlled-release OROS (Methylphenidate HCl) Formulation,&rdquo; <i>J Clin Pharmacol</i>, 2000, 40(4):379-88.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/10761165/pubmed\" target=\"_blank\" id=\"10761165\">10761165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Murphy TK, Lewin AB, Storch EA, Stock S; American Academy of Child and Adolescent Psychiatry (AACAP) Committee on Quality Issues (CQI). Practice Parameter for the assessment and treatment of children and adolescents with tic disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2013;52(12):1341-1359.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/24290467/pubmed\" target=\"_blank\" id=\"24290467\">24290467</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Institute for Health and Clinical Excellence (NICE), National Collaborating Centre for Mental Health , &ldquo;Attention Deficit Hyperactivity Disorder, The NICE Guideline on Diagnosis and Management of ADHD in Children, Young People and Adults,&rdquo; National Clinical Practice Guideline Number 72, 2008:1-664. Available at https://www.nice.org.uk/guidance/CG72</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nissen SE, &ldquo;ADHD and Cardiovascular Risk,&rdquo; <i>N Engl J Med</i>, 2006, 354(14):1445-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/16549404/pubmed\" target=\"_blank\" id=\"16549404\">16549404</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perrin JM, Friedman RA, Knilans TK; Black Box Working Group; Section on Cardiology and Cardiac Surgery. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. <i>Pediatrics</i>. 2008;122(2):451-453.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/18676566/pubmed\" target=\"_blank\" id=\"18676566\">18676566</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(7):894-921.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/17581453/pubmed\" target=\"_blank\" id=\"17581453\">17581453</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    QuilliChew (methylphenidate) extended-release chewable tablets [prescribing information]. New York, NY: Pfizer; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Quillivant XR (methylphenidate) [prescribing information]. New York, NY: Pfizer Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ritalin/Ritalin SR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ritalin LA [package insert]. East Hanover, NJ: Novartis Pharmaceuticals; December 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ritalin/Ritalin SR (methylphenidate) [product monograph]. Dorval, Quebec, Canada: Novartis Pharmaceuticals Canada Inc; June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shaywitz SE and Shaywitz BA, &ldquo;Diagnosis and Management of Attention Deficit Disorder: A Pediatric Perspective,&rdquo; <i>Pediatr Clin North Am</i>, 1984, 31(2):429-57.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/6728525/pubmed\" target=\"_blank\" id=\"6728525\">6728525</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shin JY, Roughead EE, Park BJ, Pratt NL. Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study. <i>BMJ</i>. 2016;353:i2550. doi: 10.1136/bmj.i2550.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/27245699/pubmed\" target=\"_blank\" id=\"27245699\">27245699</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Spigset O, Brede WR, and Zahlsen K, &ldquo;Excretion of Methylphenidate in Breast Milk,&rdquo; <i>Am J Psychiatry</i>, 2007, 164(2):348.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/17267805/pubmed\" target=\"_blank\" id=\"17267805\">17267805</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Thorpy M, Zhao CG, and Dauvilliers Y, &quot;Management of Narcolepsy During Pregnancy,&quot; <i>Sleep Med</i>, 2013, 14(4):367-76.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/23433999/pubmed\" target=\"_blank\" id=\"23433999\">23433999</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vetter VL, Elia J, Erickson CH, et al; American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee; American Heart Association Council on Cardiovascular Nursing. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing [published correction appears in <i>Circulation</i>. 2009;120(7):e55-e59]. <i>Circulation</i>. 2008;117(18):2407-2423.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/18427125/pubmed\" target=\"_blank\" id=\"18427125\">18427125</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7755127\"></a>Wallace AE, Kofoed LL and West AN, &ldquo;Double-Blind, Placebo-Controlled Trial of Methylphenidate in Older, Depressed, Medically Ill Patients,&rdquo; <i>Am J Psychiatry</i>, 1995, 152(6):929-31.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/7755127/pubmed\" target=\"_blank\" id=\"7755127\">7755127</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiss MD and Weiss JR, &ldquo;A Guide to the Treatment of Adults With ADHD,&rdquo; <i>J Clin Psychiatry</i>, 2004, 65(Suppl 3):27-37.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/15046533/pubmed\" target=\"_blank\" id=\"15046533\">15046533</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wilens TE and Biederman J, &ldquo;The Stimulants,&rdquo; <i>Psychiatr Clin North Am</i>, 1992, 15(1):191-222.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/methylphenidate-drug-information/abstract-text/1347939/pubmed\" target=\"_blank\" id=\"1347939\">1347939</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9638 Version 268.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709144\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F195295\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F195296\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F195328\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F195300\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F195313\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F195301\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F15967082\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F15967083\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F195272\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F195256\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F50474161\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F17983297\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Controlled Substance\" href=\"#F195330\" class=\"outlineLink\">Controlled Substance</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F7874704\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F195275\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F195274\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25469400\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F195336\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F195263\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F195278\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F195260\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F195323\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F195265\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Food Interactions\" href=\"#F195292\" class=\"outlineLink\">Food Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F195267\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F195281\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F3277308\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F195282\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F195269\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F195259\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F195277\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F5989423\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F195283\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9638|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=methylphenidate-patient-drug-information\" class=\"drug drug_patient\">Methylphenidate: Patient drug information</a></li><li><a href=\"topic.htm?path=methylphenidate-pediatric-drug-information\" class=\"drug drug_pediatric\">Methylphenidate: Pediatric drug information</a></li></ul></div></div>","javascript":null}